BMO Capital Initiates Coverage on Affimed NV(NASDAQ:AFMD). The shares have been rated Outperform. The rating by BMO Capital was issued on Apr 12, 2016.
Affimed NV (AFMD) shares turned negative on Fridays trading session with the shares closing down -0.07 points or -1.56% at a volume of 1,71,260. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $4.63. The peak price level was also seen at $4.63 while the days lowest was $4.42. Finally the shares closed at $4.43. The 52-week high of the shares is $24.2 while the 52-week low is $2.76. According to the latest information available, the market cap of the company is $147 M.
Affimed NV(AFMD) last announced its earnings results on Mar 30, 2016 for Fiscal Year 2015 and Q4.Company reported revenue of $1.88M. Analysts had an estimated revenue of $1.88M. Earnings per share were $-0.21. Analysts had estimated an EPS of $-0.19.
Affimed N.V. (Affimed) is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company’s research and development pipeline consists of AFM13 AFM11 AFM21 TandAb and Trispecific Ab. The Company’s lead candidate AFM13 is a NK-cell TandAb designed for the treatment of certain CD30-positive (CD30+) B- and T-cell malignancies including Hodgkin Lymphoma or HL. AFM11 is a T-cell TandAb designed for the treatment of certain CD19+ B-cell malignancies including non-Hodgkin Lymphoma or NHL Acute Lymphocytic Leukemia or ALL and Chronic Lymphocytic Leukemia or CLL. AFM21 selectively binds Epidermal Growth Factor Receptor variant III or EGFRvIII. The Company’s TandAbs brings NK-cells or T-cells into proximity and triggers a signal cascade that leads to the destruction of cancer cells.